Neurizon Therapeutics Limited has released a press release.
Phase I Monepantel Tablets Demonstrate High Safety
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurizon Therapeutics Limited on 6ix
Earlier from Neurizon Therapeutics
- PharmAust Raises $1.3m in Rights Issue
- MPL Tablets Demonstrate Positive Performance in Phase 1
- PharmAust Rights Issue Reaches Minimum Subscription
- Appendix 4D & Financial Report
- Offer Document - Rights Issue
Later from Neurizon Therapeutics
- Shortfall Placement Oversubscribed
- PharmAust Receives $672,250 R&D Tax Incentive Refund
- Phase I Canine Repeat Dose MPL Demonstrates High Performance
- Receipt of 25kg of GMP-Grade Monepantel from Elanco
- PharmAust Commences GMP Tablet Manufacture for Phase 2 Trial
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics